Abstract
Various preclinical studies with developed Eustachian tube (ET) stents are in progress but have not yet been clinically applied. ET stent is limited by stent-induced tissue hyperplasia in preclinical studies. The effectiveness of sirolimus-eluting cobalt–chrome alloy stent (SES) in suppressing stent-induced tissue hyperplasia after stent placement in the porcine ET model was investigated. Six pigs were divided into two groups (i.e., the control and the SES groups) with three pigs for each group. The control group received an uncoated cobalt–chrome alloy stent (n = 6), and the SES group received a sirolimus-eluting cobalt–chrome alloy stent (n = 6). All groups were sacrificed 4 weeks after stent placement. Stent placement was successful in all ETs without procedure-related complications. None of the stents was able to keep its round shape as original, and mucus accumulation was observed inside and around the stent in both groups. On histologic analysis, the tissue hyperplasia area and the thickness of submucosal fibrosis were significantly lower in the SES group than in the control group. SES seems to be effective in suppressing stent-induced tissue hyperplasia in porcine ET. However, further investigation was required to verify the optimal stent materials and antiproliferative drugs.
Highlights
Various preclinical studies with developed Eustachian tube (ET) stents are in progress but have not yet been clinically applied
This study aims to investigate the effectiveness of sirolimus-eluting cobalt–chrome alloy stent (SES) in suppressing stent-induced tissue hyperplasia after stent placement in the porcine ET model
Pharmacologic agents such as dexamethasone, paclitaxel, gemcitabine, EW-7197, and sirolimus are coated onto the surface of stent wire meshes or covering membrane to prevent or treat tissue hyperplasia after stent p lacement[29,30,34–36]
Summary
Various preclinical studies with developed Eustachian tube (ET) stents are in progress but have not yet been clinically applied. ET stent is limited by stent-induced tissue hyperplasia in preclinical studies. The effectiveness of sirolimus-eluting cobalt–chrome alloy stent (SES) in suppressing stent-induced tissue hyperplasia after stent placement in the porcine ET model was investigated. SES seems to be effective in suppressing stent-induced tissue hyperplasia in porcine ET. Current ET dysfunction treatments (e.g., nasal surgery, ventilation tube insertion, and pharmacologic agents) have been applied in patients. These treatments were limited in their effectiveness and may result in ET obstruction, infection, and permanent perforation of the tympanic membrane[3,6,7]. This study aims to investigate the effectiveness of sirolimus-eluting cobalt–chrome alloy stent (SES) in suppressing stent-induced tissue hyperplasia after stent placement in the porcine ET model
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have